PSI Structural Biology Knowledgebase

PSI | Structural Biology Knowledgebase
Header Icons

Related Articles
Protein Folding and Misfolding: It's the Journey, Not the Destination
March 2015
CCR5 and HIV Infection
January 2015
HIV/AIDS: Pre-fusion Env Exposed
January 2015
HIV/AIDS: Slide to Enter
January 2015
Updating ModBase
January 2015
Power in Numbers
August 2014
Quorum Sensing: A Groovy New Component
August 2014
Bacterial CDI Toxins
June 2014
Immunity: One Antibody to Rule Them All
June 2014
Virology: A Bat Influenza Hemagglutinin
March 2014
Virology: Making Sensitive Magic
March 2014
Virology: Visualizing Cyanophage Assembly
March 2014
Virology: Zeroing in on HBV Egress
March 2014
March 2014
Cas4 Nuclease and Bacterial Immunity
February 2014
Microbial Pathogenesis: A GNAT from Pseudomonas
February 2014
Microbial Pathogenesis: Targeting Drug Resistance in Mycobacterium tuberculosis
February 2014
Microbiome: The Dynamics of Infection
September 2013
Membrane Proteome: A Funnel-like Viroporin
August 2013
Infectious Diseases: A Pathogen Ubiquitin Ligase
May 2013
Infectious Diseases: A Shared Syringe
May 2013
Infectious Diseases: Determining the Essential Structome
May 2013
Infectious Diseases: Targeting Meningitis
May 2013
NDM-1 and Antibiotics
May 2013
Bacterial Hemophores
January 2013
Microbial Pathogenesis: Computational Epitope Prediction
January 2013
Microbial Pathogenesis: Influenza Inhibitor Screen
January 2013
Microbial Pathogenesis: Measles Virus Attachment
January 2013
Microbial Pathogenesis: NEAT Iron
January 2013
Membrane Proteome: Sphingolipid Synthesis Selectivity
December 2012
A signal sensing switch
September 2012
Gauging needle structure
July 2012
Anthrax Stealth Siderophores
June 2012
A Pseudomonas L-serine dehydrogenase
May 2012
Pilus Assembly Protein TadZ
April 2012
Making Lipopolysaccharide
January 2012
Superbugs and Antibiotic Resistance
December 2011
A change to resistance
November 2011
An effective and cooperative dimer
November 2011
The Perils of Protein Secretion
November 2011
Bacterial Armor
October 2011
Breaking down the defenses
September 2011
Moving some metal
August 2011
Capsid assembly in motion
April 2011
Know thy enemy … structurally
October 2010
Treating sleeping sickness
May 2010
Bacterial spore kinase
April 2010
Hemolysin BL
January 2010
Unusual cell division
October 2009
Anthrax evasion tactics
September 2009
Toxin-antitoxin VapBC-5
September 2009
Antibiotic target
August 2009
July 2009
Tackling influenza
June 2009
You look familiar: the Type VI secretion system
June 2009
Unique SARS
April 2009
Anthrax stealth molecule
March 2009
A new class of bacterial E3 ubiquitination enzymes
January 2009
Antiviral evasion
October 2008
SARS connections
September 2008
SARS Coronavirus Nonstructural Protein 1
June 2008

Research Themes Infectious diseases

Treating sleeping sickness

PSI-SGKB [doi:10.1038/fa_psisgkb.2010.16]
Featured Article - May 2010
Short description: A potential new drug kills the bloodstream parasite that causes this disease.

X-ray crystal structure of DDD85646 bound to LmN-myristoyltransferase.

African sleeping sickness, also known as human African trypanosomiasis, kills 30,000 people each year, and there is currently no effective and safe treatment. Frearson et al. from the University of Dundee, in collaboration with the University of York and the Structural Genomics Consortium in Toronto, report a new potential drug that kills the bloodstream parasite that causes this disease.

N-myristoylation is an important eukaryotic modification required for many biological processes. In the parasite that causes sleeping sickness, Trypanosoma brucei, this reaction is catalysed by N-myristoyltransferase, which has at least 60 substrates and is probably involved in many downstream processes. The central role of this enzyme suggested that its inhibition might be an effective way to treat the disease.

This isn't the first time N-myristoyltransferase has attracted attention though. It has been investigated as a potential anticancer, antiviral and antifungal target, too, and looks promising as a drug target because it is possible to distinguish between the human and the parasitic form. Unfortunately, no useful and safe inhibitors have been identified until now.

But anti-fungal N-myristoyltransferase programs were discontinued because of an inability to identify broad spectrum inhibitors. And as for cancer treatment, no one has yet identified potent human N-myristoyltransferase inhibitors with which to fully validate this enzyme.

Frearson et al. screened 62,000 compounds for a potential lead and eventually identified one, DDD85646, that inhibits N-myristoyltransferase and prevents growth of T. brucei. Testing of this potential drug in a mouse model of human African trypanosomiasis proved successful, with all mice cured of this disease when the compound was taken orally. Even mice with a clinically relevant form T. brucei rhodesiense were cured.

These promising results against T. brucei in the bloodstream make DDD85646 an exciting prospect for drug development, but an effective treatment needs to also work at a later stage of infection, when T. brucei has crossed into the central nervous system. Ideally, its selectivity for the T. brucei N-myristoyltransferase rather than the human form should be improved too. To enhance DD85646, it's important to understand how it works, and that's where the Structural Genomics Consortium helped out.

Inhibition assays had indicated that DDD85646 competes with the peptide substrate, but in the absence of a three-dimensional structure of N-myristoyltransferase the exact mechanism was not known. T. brucei N-myristoyltransferase would not crystallize but the highly similar Leishmania major form, which has 74% sequence identity with TbNMT and 94% identity within the peptide binding site, did.

The structure revealed that DDD85646 does indeed bind in the peptide substrate pocket of N-myristoyltransferase, but the structure showed something very interesting: the interactions between the compound and enzyme are mostly through water-mediated interactions rather than normal hydrogen bonding. Computer modeling of this complex is highly unlikely to have been able to predict this, illustrating the importance of obtaining the actual structure.

Related articles

The cancer kinome

Safer Alzheimer's drugs

Two component signaling

Maria Hodges


  1. J. A. Frearson et al. N-myristoyltransferase inhibitors as new leads to treat sleeping sickness.
    Nature 464, 728-732 (2010). doi:10.1038/nature08893

Structural Biology Knowledgebase ISSN: 1758-1338
Funded by a grant from the National Institute of General Medical Sciences of the National Institutes of Health